WCLC-话题@MedSci

#WCLC#

72篇内容 | 2506人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1412373, encodeId=354814123e338, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, objectType=article, longId=179499, objectId=164d1e9499e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d1e9499e1, replyNumber=0, likeNumber=92, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d1e9499e1, moduleTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d1e9499e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412372, encodeId=202114123e2ce, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, objectType=article, longId=179498, objectId=3c141e949899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c141e949899, replyNumber=0, likeNumber=87, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c141e949899, moduleTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c141e949899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412371, encodeId=342214123e120, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, objectType=article, longId=179497, objectId=19c31e9497c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19c31e9497c1, replyNumber=0, likeNumber=68, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19c31e9497c1, moduleTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19c31e9497c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412370, encodeId=0c3c14123e029, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, objectType=article, longId=179242, objectId=f5951e9242cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5951e9242cd, replyNumber=0, likeNumber=85, createdTime=2019-09-12, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5951e9242cd, moduleTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5951e9242cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412369, encodeId=df6814123693c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019：mNSCLC中的敏感性或耐药性突变, objectType=article, longId=179177, objectId=e8111e9177ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8111e9177ca, replyNumber=0, likeNumber=64, createdTime=2019-09-11, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8111e9177ca, moduleTitle=WCLC 2019：mNSCLC中的敏感性或耐药性突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8111e9177ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412368, encodeId=b787141236808, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, objectType=article, longId=179176, objectId=99521e9176c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99521e9176c4, replyNumber=0, likeNumber=78, createdTime=2019-09-10, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99521e9176c4, moduleTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99521e9176c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412367, encodeId=7c49141236eac, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤, objectType=article, longId=179175, objectId=f41b1e9175df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f41b1e9175df, replyNumber=0, likeNumber=62, createdTime=2019-09-10, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f41b1e9175df, moduleTitle=WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f41b1e9175df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412366, encodeId=40bd14123668e, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019 抢先看∣SCLC患者接受免疫治疗后，6周内出现irAE疗效更好, objectType=article, longId=178880, objectId=4b511e888018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b511e888018, replyNumber=0, likeNumber=60, createdTime=2019-09-06, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b511e888018, moduleTitle=WCLC 2019 抢先看∣SCLC患者接受免疫治疗后，6周内出现irAE疗效更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b511e888018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412365, encodeId=785f141236520, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2019抢先看∣作为当前探讨的热点，免疫治疗超进展又有哪些新近进展？, objectType=article, longId=178772, objectId=c6911e877262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6911e877262, replyNumber=0, likeNumber=73, createdTime=2019-09-05, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6911e877262, moduleTitle=WCLC 2019抢先看∣作为当前探讨的热点，免疫治疗超进展又有哪些新近进展？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6911e877262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412364, encodeId=5cc51412364f3, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, objectType=article, longId=150187, objectId=c14115018eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c14115018eac, replyNumber=0, likeNumber=73, createdTime=2018-10-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c14115018eac, moduleTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c14115018eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412363, encodeId=a2c014123634b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, objectType=article, longId=150184, objectId=a0d515018464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d515018464, replyNumber=0, likeNumber=68, createdTime=2018-10-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d515018464, moduleTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d515018464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412362, encodeId=8e091412362ef, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=【WCLC 2018】程颖教授谈小细胞肺癌研究进展, objectType=article, longId=150181, objectId=34ce150181dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ce150181dd, replyNumber=0, likeNumber=63, createdTime=2018-10-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ce150181dd, moduleTitle=【WCLC 2018】程颖教授谈小细胞肺癌研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34ce150181dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412361, encodeId=90f814123613c, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=【2018WCLC】小细胞肺癌：阿帕替尼单药或联合化疗锋芒初露，有望成为新的获益选择, objectType=article, longId=150101, objectId=585b150101f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585b150101f6, replyNumber=0, likeNumber=67, createdTime=2018-10-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585b150101f6, moduleTitle=【2018WCLC】小细胞肺癌：阿帕替尼单药或联合化疗锋芒初露，有望成为新的获益选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=585b150101f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412360, encodeId=986c1412360e6, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待, objectType=article, longId=150100, objectId=a38a150100d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a150100d9, replyNumber=0, likeNumber=68, createdTime=2018-10-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a150100d9, moduleTitle=2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38a150100d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412359, encodeId=b80b14123597b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性, objectType=article, longId=149961, objectId=921f1499613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921f1499613d, replyNumber=0, likeNumber=75, createdTime=2018-09-30, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921f1499613d, moduleTitle=2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921f1499613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412358, encodeId=2006141235821, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, objectType=article, longId=149831, objectId=c67914983121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67914983121, replyNumber=0, likeNumber=0, createdTime=2018-09-29, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67914983121, moduleTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c67914983121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412357, encodeId=95b5141235ea0, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, objectType=article, longId=149829, objectId=2dc21498290c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc21498290c, replyNumber=0, likeNumber=80, createdTime=2018-09-29, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc21498290c, moduleTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc21498290c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412356, encodeId=d2b71412356de, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=【2018 WCLC】关注安罗替尼治疗后的生活质量和不良反应管理, objectType=article, longId=149759, objectId=70fe149e592f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70fe149e592f, replyNumber=0, likeNumber=80, createdTime=2018-09-29, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70fe149e592f, moduleTitle=【2018 WCLC】关注安罗替尼治疗后的生活质量和不良反应管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70fe149e592f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412355, encodeId=0103141235560, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=郭人花教授点评2017 WCLC中国好声音, objectType=article, longId=118520, objectId=47da118520f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47da118520f9, replyNumber=0, likeNumber=0, createdTime=2017-11-04, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47da118520f9, moduleTitle=郭人花教授点评2017 WCLC中国好声音, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47da118520f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412354, encodeId=7e4d14123540b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, objectType=article, longId=118378, objectId=d0071183e824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0071183e824, replyNumber=0, likeNumber=74, createdTime=2017-11-03, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0071183e824, moduleTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0071183e824)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

WCLC

2020-05-29

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC

2019-09-12

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019：mNSCLC中的敏感性或耐药性突变

2019-09-11

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法

2019-09-10

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019：KRAS抑制剂AMG 510显著缩小了NSCLC患者的肿瘤

2019-09-10

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019 抢先看∣SCLC患者接受免疫治疗后，6周内出现irAE疗效更好

2019-09-06

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2019抢先看∣作为当前探讨的热点，免疫治疗超进展又有哪些新近进展？

2019-09-05

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切

2018-10-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索

2018-10-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

【WCLC 2018】程颖教授谈小细胞肺癌研究进展

2018-10-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

【2018WCLC】小细胞肺癌：阿帕替尼单药或联合化疗锋芒初露，有望成为新的获益选择

2018-10-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2018 WCLC | 张力教授：Keynote－032结果公布，Keynote－033值得期待

2018-10-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性

2018-09-30

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS

2018-09-29

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率

2018-09-29

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

【2018 WCLC】关注安罗替尼治疗后的生活质量和不良反应管理

2018-09-29

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

郭人花教授点评2017 WCLC中国好声音

2017-11-04

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点

2017-11-03

科室
- - 订阅+
  - 更多科室
工具
服务